The corneal inlay had extruded through the flap and was not available for analysis.The device history record review of the manufacturing lot for this device was performed and there were no discrepancies or unusual findings related to the reported issue.Corneal melting, corneal scarring, corneal inflammation, loss of vision, and increased visual symptoms are listed in the device labeling as known potential risks.Complaint reference number: (b)(4).
|
The subject was enrolled in the u.S.Ide clinical trial and underwent implantation of the investigational raindrop corneal inlay in the left eye on (b)(6) 2013.Four years postoperatively the subject was diagnosed by an ophthalmologist (not the study investigator) with (b)(6) over the inlay and was prescribed steroids and antiviral medications for 2 weeks with no resolution.The patient was later seen by the ide investigator who did not confirm the diagnosis of (b)(6), but instead reported focal dense central scarring anterior and posterior to the inlay with melting of the stroma and disruption of the epithelium directly over the inlay with very poor vision.The patient was prescribed steroids and the inlay was scheduled to be explanted.During the intervention, the inlay was not removed because it had extruded through the flap.Additional information is being requested.In addition to the report from the study investigator, the study subject also contacted the manufacturer and reported experiencing ocular irritation, sensitivity to light, and eye tearing.The patient denies having a medical history of (b)(6), but disclosed he has allergies and admitted to eye rubbing.
|